TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35236723

Group type: EXPERIMENTAL
Intervention: Intensive surveillance (arm B) including AFB every 6 months
Number of subjects: 364

Group type: COMPARATOR
Intervention: Standard surveillance (arm A) with CT and AFB at 36 months
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Mild or moderate dysplasia at baseline bronchoscopy
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 364
Study: 33401126

Group type: EXPERIMENTAL
Intervention: SPSRS application intervention for approximately 10 min/a day for 5 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (wait list control group)
Number of subjects: 32
Study: 35218033

Group type: EXPERIMENTAL
Intervention: Randomized plans without stopping criteria
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bayesian plans without stopping criteria
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Randomized plans with stopping criteria
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bayesian plans with stopping criteria
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manually generated plans
Number of subjects: 10
Study: 32279518

Group type: EXPERIMENTAL
Intervention: 12-hour comprehensive nutrition care (12h-HNC), n=158
Number of subjects: 312

Group type: COMPARATOR
Intervention: Traditional one-time nutrition guidance (control group), n=154
Number of subjects: 312
Study: 616406917

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg administered during 10 minutes before induction, then 15 mg/kg/hour during surgery)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (normal saline administered in the same manner)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 110
Study: 34129469

Group type: EXPERIMENTAL
Intervention: 2 mm-core TMAs using PD-1 NAT105 and PD-L1 28.8 antibodies with a 5% cut off for positivity on tumor-infiltrating immune cells (TILs) and tumor cells.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.6 mm-core TMAs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Whole tissue sections (WTS)
Number of subjects: 22
Study: 35848047

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with respiratory training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine swallowing rehabilitation training and respiratory training (Control)
Number of subjects: 64
Study: 33303340

Group type: EXPERIMENTAL
Intervention: Pain self-management intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical detection threshold increase
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Windup ratio increase
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OXTR rs2254298 minor allele presence
Number of subjects: 60
Study: 32491236

Group type: EXPERIMENTAL
Intervention: McGill Denture Satisfaction Questionnaire (MDSQ) - overall satisfaction, retention/stability, aesthetics, cleaning, speech, comfort, general chewing ability
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: McGill Denture Satisfaction Questionnaire (MDSQ) - mastication of specific foods
Number of subjects: 265
Study: 34811741

Group type: EXPERIMENTAL
Intervention: Days alive without life support (DAWOLS) at day 28 and 90
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Days alive and out of hospital (DAAOOH) at day 28 and 90
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessed using the EuroQol EQ-5D-5L questionnaire (EQ-VAS and EQ-5D-5L index values)
Number of subjects: 0
Study: 33979372

Group type: EXPERIMENTAL
Intervention: Gait retraining focusing on impact (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gait retraining focusing on cadence (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 0
Study: 35566210

Group type: EXPERIMENTAL
Intervention: BCP-SEDDS (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: BCP neat oil
Number of subjects: 24
Study: 32301523

Group type: EXPERIMENTAL
Intervention: Thumb orthosis (Push Ortho and immediate fitting, IMF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Thumb-wrist orthosis (Ligaflex Manu and IMF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Without orthosis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prefabricated orthoses
Number of subjects: 18
Study: 33387724

Group type: EXPERIMENTAL
Intervention: Resveratrol (400 mg) for 12–14 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (400 mg) for 12–14 weeks
Number of subjects: 34
Study: 34775507

Group type: EXPERIMENTAL
Intervention: n-of-1 trials of self-selected AF triggers
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Alcohol exposure
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Other exposures (caffeine, etc.)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (AF monitoring only)
Number of subjects: 446
Study: 32374822

Group type: EXPERIMENTAL
Intervention: RAPID
Number of subjects: 448

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 448
Study: 32605809

Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 57

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 57
Study: 34762555

Group type: EXPERIMENTAL
Intervention: Moderate muscle damage group (MoDG) - 30 maximal eccentric isokinetic contractions at 60 degrees/s
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mild muscle damage group (MiDG) - 10 maximal eccentric isokinetic contractions at 60 degrees/s
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 30
Study: 33492303

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg/d for 2 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 39
Study: 32794398

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 + citrate dentifrice A
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 + sodium hexametaphosphate dentifrice B
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 + pyrophosphate dentifrice C
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate negative control
Number of subjects: 120
Study: 36224697

Group type: EXPERIMENTAL
Intervention: Whole-process case management (group W)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Traditional perioperative case management (group G)
Number of subjects: 204
Study: 34813408

Group type: EXPERIMENTAL
Intervention: Low-dose vaginal 17β-estradiol tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vaginal promestriene cream
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 33517579

Group type: EXPERIMENTAL
Intervention: Narrative patient testimonials
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Non-narrative decision strategies
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control group (unrelated text)
Number of subjects: 334
Study: 35621697

Group type: EXPERIMENTAL
Intervention: HLA DQA1*03:01-B1*03:02 (DQ8/8)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: HLA DQA1*03:03-B1*03:01
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: DQ*VA
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: DQ*AD
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: VA/VA (DQA1*03:01-B1*03:02)
Number of subjects: 670
Study: 34264825

Group type: EXPERIMENTAL
Intervention: Automated algorithms for predicting lung nodule malignancy from sequential LDCT scans
Number of subjects: 100

Group type: COMPARATOR
Intervention: Volume change estimate
Number of subjects: 100
Study: 36006643

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 482

Group type: COMPARATOR
Intervention: Dexamethasone with mycophenolate
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Composite outcome of ESKD or 40% decline in eGFR
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Complete and/or partial remission of proteinuria
Number of subjects: 482
Study: 32801167

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (10 mg, cumulative dose 3.5 mg/kg over 2 years)
Number of subjects: 3150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3150
Study: 34821063

Group type: EXPERIMENTAL
Intervention: Telephone support
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: SMS support
Number of subjects: 797

Group type: COMPARATOR
Intervention: Control
Number of subjects: 797
Study: 33439486

Group type: EXPERIMENTAL
Intervention: Fostamatinib as second-line therapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Fostamatinib as third-or-later-line therapy
Number of subjects: 145
Study: 35766811

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg at week 0, week 4, then Q8W
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Placebo (crossover to guselkumab at week 24)
Number of subjects: 1120
Study: 33627111

Group type: EXPERIMENTAL
Intervention: MEBO ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MEBO and Diltiazem ointments
Number of subjects: 0
Study: 34310866

Group type: EXPERIMENTAL
Intervention: Naringenin (NAR)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Azithromycin (AZI)
Number of subjects: 180
Study: 33731648

Group type: EXPERIMENTAL
Intervention: Exercised (treadmill exercise session at the beginning of the fast)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonexercised (no treadmill exercise session at the beginning of the fast)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercised
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonexercised
Number of subjects: 20
Study: 33321849

Group type: EXPERIMENTAL
Intervention: Telephone-coaching group (TC)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group without telephone-coaching (noTC)
Number of subjects: 103
Study: 35940841

Group type: EXPERIMENTAL
Intervention: Prescription digital therapeutic (PDT) for mobile-delivered CBT-I (Somryst)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100
Study: 34362786

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 4277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4277
Study: 34658285

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure and exercise
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Combination of acupressure and exercise
Number of subjects: 221
Study: 34887180

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol (group P)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 33041146

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Magnesium, Metoclopramide, Prochlorperazine
Number of subjects: 157
Study: 33902763

Group type: EXPERIMENTAL
Intervention: Exercise + hot drink (60°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exercise + cold drink (2°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exercise (no preload)
Number of subjects: 12
Study: 33724592

Group type: EXPERIMENTAL
Intervention: Standardized extract of Opuntia ficus-indica (400 mg/day) for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32078062

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (180 J) with infrared (IR 940 ± 10 nm)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (180 J) with mixed Red and IR (RED/IR 620 + 940 nm)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham (disabled device)
Number of subjects: 48
Study: 35729664

Group type: EXPERIMENTAL
Intervention: Media Aware (asynchronous, web‐based media literacy education program)
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Active control (sexual health education from Media Aware without MLE content or methods)
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 2010
Study: 32054535

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including targeted health education, improved hospital CS policy, and training of midwives/doulas for 8 months.
Number of subjects: 21273

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 21273

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 21273
Study: 33813917

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 486
Study: 32301137

Group type: EXPERIMENTAL
Intervention: Relamorelin 10 µg once or twice daily
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Relamorelin 10, 30 or 100 µg
Number of subjects: 597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study: 36293723

Group type: EXPERIMENTAL
Intervention: Curved environment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Linear environment
Number of subjects: 40
Study: 34351939

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care (initiate amlodipine only if hypertension develops)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Prehypertension treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 250
Study: 85049646

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 25 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35513777

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program with a motivational interview consisting of four motivational interviews and visits with family physicians, primary healthcare nurses, and a cardiologist.
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard primary healthcare (control group).
Number of subjects: 284
Study: 32869151

Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg once daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Solifenacin (5 mg once daily)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 92

Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 92
Study: 35370486

Group type: EXPERIMENTAL
Intervention: Propranolol (nonselective β-antagonist) administered for 1 week prior to and 4 weeks following HCT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no propranolol treatment)
Number of subjects: 25
Study: 33715235

Group type: EXPERIMENTAL
Intervention: Peanut Oral Food Challenge (OFC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Consumption of a light meal 1 h after reaction
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Symptomatic postural fall in blood pressure noted in preparation for discharge
Number of subjects: 121
Study: 616389131

Group type: EXPERIMENTAL
Intervention: Two-port retroperitoneal laparoscopy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional three-port retroperitoneal laparoscopic surgery
Number of subjects: 80
Study: 35162896

Group type: EXPERIMENTAL
Intervention: Active posters
Number of subjects: 175

Group type: COMPARATOR
Intervention: Nature posters
Number of subjects: 175
Study: 33953221

Group type: EXPERIMENTAL
Intervention: High Nitrogen (HN)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Low Nitrogen (LN)
Number of subjects: 202
Study: 32406987

Group type: EXPERIMENTAL
Intervention: Child mouthing of soil
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Presence of animals in sleeping space
Number of subjects: 553
Study: 35341657

Group type: EXPERIMENTAL
Intervention: Mother-sung lullabies
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no lullabies)
Number of subjects: 60
Study: 33388444

Group type: EXPERIMENTAL
Intervention: Etonogestrel subdermal contraceptive implant (SCI)
Number of subjects: 540
Study: 32378724

Group type: EXPERIMENTAL
Intervention: Herring roe oil supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33300296

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 5929

Group type: COMPARATOR
Intervention: Syntometrine
Number of subjects: 5929

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 5929
Study: 35348764

Group type: EXPERIMENTAL
Intervention: Polypharmacy (≥5 medications)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Excessive polypharmacy (≥10 medications)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIM)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Cardiovascular medications
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Nonprescription medications
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Potential major drug-drug interactions (DDI)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Potential major drug-cancer treatment interactions (DCI)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Each additional medication
Number of subjects: 718
Study: 32151439

Group type: EXPERIMENTAL
Intervention: Professional e-mail counseling
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Peer-led Web discussion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Interpersonal support
Number of subjects: 200
Study: 36284645

Group type: EXPERIMENTAL
Intervention: Favipiravir 1800 mg on day 1, then 800 mg twice daily for 14 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 33075200

Group type: EXPERIMENTAL
Intervention: Self-regulation behaviour change techniques (BCTs)
Number of subjects: 12
Study: 35419334

Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC) teaching
Number of subjects: 119

Group type: COMPARATOR
Intervention: Traditional Lecture (TL) teaching
Number of subjects: 119
Study: 32439189

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin patch (5 mg) applied 1 hour before anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with gauze pad applied to bare skin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin patch (5 mg)
Number of subjects: 40
Study: 34864695

Group type: EXPERIMENTAL
Intervention: Multimodal stimulation (MMS) for 5 days, 30 minutes/session, totaling five sessions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 34392585

Group type: EXPERIMENTAL
Intervention: Various land-use histories
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Local space-for-time comparisons
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Research in temperate forested biomes
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Research priorities and data gaps
Number of subjects: 4000
Study: 32356581

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVB) 1.25 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TCA) 4 mg
Number of subjects: 61
Study: 36273203

Group type: COMPARATOR
Intervention: Current standard-of-care anticoagulation practice
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: HA-VTE risk probability calculated from a validated VTE risk-prediction model with daily updates and additional review by hematologists for patients with elevated risk (predicted probability of HA-VTE ≥ 0.025)
Number of subjects: 15000
Study: 34214614

Group type: EXPERIMENTAL
Intervention: Focal boost to external beam radiotherapy (EBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT) without focal boost
Number of subjects: 0
Study: 35065008

Group type: EXPERIMENTAL
Intervention: Three-step support strategy (physician-driven, nurse-aided) including family conference, ICU-room visit, and post-death meeting.
Number of subjects: 875

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 875
Study: 33741550

Group type: EXPERIMENTAL
Intervention: Screening by clinical breast examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32589630

Group type: EXPERIMENTAL
Intervention: Vienna Prediction Model (VPM) guided anticoagulant treatment
Number of subjects: 883

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 883
Study: 35783617

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation combined with auricular acupressure
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 210
Study: 33275596

Group type: EXPERIMENTAL
Intervention: Genetically predicted alcohol consumption
Number of subjects: 1200000

Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking
Number of subjects: 1200000
Study: 36097826

Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 98

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 98
Study: 33336888

Group type: EXPERIMENTAL
Intervention: Low-dose glucagon (150 μg subcutaneous)
Number of subjects: 10
Study: 33221955

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 73
Study: 35112582

Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 500

Group type: COMPARATOR
Intervention: Flipchart presentation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both interventions (video and flipchart)
Number of subjects: 500
Study: 33521870

Group type: COMPARATOR
Intervention: Scaling and root planing alone (SRP alone)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Scaling and root planing with diode laser (SRP + DL)
Number of subjects: 44
Study: 33032658

Group type: EXPERIMENTAL
Intervention: Saccharibacteria
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Prostate cancer
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus and chronic myeloid leukaemia
Number of subjects: 1475